Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2016

Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2016
Published Aug 10, 2016
376 pages — Published Aug 10, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2016, provides an overview of the Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)
- The report reviews pipeline therapeutics for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) therapeutics and enlists all their major and minor projects
- The report assesses Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- P

  
Source:
Document ID
GMDHC8349IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents211
  List of Tables111
  List of Figures121
Introduction131
  Global Markets Direct Report Coverage131
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Overview141
Therapeutics Development152
  Pipeline Products for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Overview151
  Pipeline Products for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Comparative Analysis161
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Therapeutics under Development by Companies173
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Therapeutics under Investigation by Universities/Institutes201
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Pipeline Products Glance213
  Late Stage Products211
  Clinical Stage Products221
  Early Stage Products231
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Products under Development by Companies244
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Products under Investigation by Universities/Institutes281
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Companies Involved in Therapeutics Development2941
  4SC AG291
  AbbVie Inc301
  Acetylon Pharmaceuticals, Inc.311
  Actinium Pharmaceuticals, Inc.321
  ADC Therapeutics Sarl331
  Affimed GmbH341
  Amgen Inc.351
  Arno Therapeutics, Inc.361
  Bellicum Pharmaceuticals, Inc.371
  Bristol-Myers Squibb Company381
  Celgene Corporation391
  Cell Medica Limited401
  Cellular Biomedicine Group, Inc.411
  Constellation Pharmaceuticals, Inc.421
  Curis, Inc.431
  Faron Pharmaceuticals Oy441
  Gamida Cell Ltd.451
  Incyte Corporation461
  Merck &Co., Inc.471
  Merck KGaA481
  Mesoblast Limited491
  Millennium Pharmaceuticals Inc501
  Mirati Therapeutics Inc.511
  Molecular Templates Inc.521
  NantKwest, Inc.531
  Ono Pharmaceutical Co., Ltd.541
  Pfizer Inc.551
  Philogen S.p.A.561
  Polyphor Ltd.571
  Rich Pharmaceuticals, Inc.581
  Seattle Genetics, Inc.591
  Selvita S.A.601
  Sigma-Tau S.p.A.611
  Spectrum Pharmaceuticals, Inc.621
  Stemline Therapeutics, Inc.631
  Taiwan Liposome Company, Ltd.641
  Takeda Pharmaceutical Company Limited651
  TG Therapeutics, Inc.661
  Theravectys SA671
  TRACON Pharmaceuticals, Inc.681
  Trillium Therapeutics Inc.691
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Therapeutics Assessment7017
  Assessment by Monotherapy Products701
  Assessment by Combination Products711
  Assessment by Target725
  Assessment by Mechanism of Action776
  Assessment by Route of Administration832
  Assessment by Molecule Type852
Drug Profiles87270
  (INCB-039110 + INCB-040093) Drug Profile871
  ADCT-301 Drug Profile881
  AFM-13 Drug Profile894
  Alocrest Drug Profile932
  AR-42 Drug Profile952
  avelumab Drug Profile975
  azacitidine Drug Profile1025
  balixafortide Drug Profile1072
  BC-8Y90 Drug Profile1091
  BMS-986016 Drug Profile1102
  BPX-501 Drug Profile1124
  brentuximab vedotin Drug Profile11624
  CBM-C30.1 Drug Profile1401
  Cellular Immunotherapy for Hodgkin Lymphoma and Non-Hodgkin Lymphoma Drug Profile1411
  Cellular Immunotherapy for Oncology Drug Profile1421
  Cellular Immunotherapy for Oncology Drug Profile1431
  Cellular Immunotherapy to Target CD30 for Hodgkin and Non-Hodgkin Lymphomas Drug Profile1441
  Cellular Immunotherapy to Target CD30 for Hodgkin and Non-Hodgkin Lymphomas Drug Profile1451
  Cellular Immunotherapy to Target GM-CSF for Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Drug Profile1461
  Cellular Immunotherapy to Target GM-CSF for Solid Tumor and Hematological Cancer Drug Profile1471
  Cellular Immunotherapy to Target LMP, BARF-1 and EBNA1 for EBV Associated Cancers and Infection Drug Profile1481
  Cellular Immunotherapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases Drug Profile1491
  Cellular Immunotherapy to Target NY-ESO-1, MAGEA4, PRAME, Survivin and Synovial Sarcoma X for Oncology Drug Profile1501
  CMD-003 Drug Profile1512
  CPI-0610 Drug Profile1531
  CUDC-907 Drug Profile1545
  Epstein-Barr virus vaccine Drug Profile1591
  Ferritarg Drug Profile1601
  FP-1305 Drug Profile1612
  haNK Program Drug Profile1631
  ibrutinib Drug Profile16425
  INCB-40093 Drug Profile1891
  Indimitecan Drug Profile1901
  Indotecan hydrochloride Drug Profile1911
  Iomab-B Drug Profile1925
  ipilimumab Drug Profile1978
  ixazomib citrate Drug Profile2059
  lirilumab Drug Profile2144
  MK-2206 Drug Profile2183
  mocetinostat Drug Profile2215
  Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies and Bacterial Infections Drug Profile2261
  MPC-CBE Drug Profile2272
  MT-17000 Drug Profile2291
  NiCord Drug Profile2303
  nivolumab Drug Profile23328
  NL-101 Drug Profile2612
  ONX-0801 Drug Profile2632
  pembrolizumab Drug Profile26531
  PF-06801591 Drug Profile2961
  PNK-007 Drug Profile2971
  procarbazine hydrochloride Drug Profile2981
  radretumab Drug Profile2992
  resminostat Drug Profile30110
  ricolinostat Drug Profile3118
  RP-323 Drug Profile3192
  ruxolitinib phosphate Drug Profile32112
  sapanisertib Drug Profile3333
  SEA-CD40 Drug Profile3361
  SEL-24B489 Drug Profile3371
  SL-101 Drug Profile3381
  SL-501 Drug Profile3391
  Small Molecule to Inhibit ADAM-10 for Hodgkin Lymphoma Drug Profile3401
  temsirolimus Drug Profile3412
  TGR-1202 Drug Profile3437
  TRC-102 Drug Profile3502
  TTI-621 Drug Profile3523
  Vaccine for Nasopharyngeal Cancer and Hodgkin Lymphoma Drug Profile3551
  vinorelbine tartrate Drug Profile3561
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Dormant Projects3574
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Discontinued Products3611
Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Product Development Milestones36213
  Featured News &Press Releases3621
    Jul 18, 2016: Seattle Genetics and Takeda Announce Publication of Final Data from ADCETRIS (Brentuximab Vedotin) Monotherapy Pivotal Phase 2 Clinical Trial in Relapsed or Refractory Classical Hodgkin Lymphoma in Blood3622
    Jul 06, 2016: Takeda Receives European Commission Approval of ADCETRIS (brentuximab vedotin) for Consolidation Treatment in Post-Transplant Hodgkin Lymphoma3641
    Jun 21, 2016: Rich Pharmaceuticals Retains Theradex Systems To Help Advance Its Hodgkin Lymphoma Indication3641
    Jun 10, 2016: New Data on Bristol-Myers Squibbs Opdivo (nivolumab) Indicate Benefit in Heavily Pre-Treated Classical Hodgkin Lymphoma Patients in Phase 2, Single-Arm Pivotal Trial3651
    Jun 09, 2016: Bristol-Myers Squibb to Present New Data on Opdivo (nivolumab) at the 21st Congress of the European Hematology Association3661
    Jun 06, 2016: KEYTRUDA (pembrolizumab) Shows Overall Response Rates of 73 to 83 Percent, with Complete Response Rates of 27 to 30 Percent, in Heavily Pre-treated Patients with cHL, in Update to Study KN-0873671
    May 31, 2016: Mundipharma EDO Announces First-in-human Clinical Trial of its Lead Compound, EDO-S1013681
    May 27, 2016: Takeda Receives Positive CHMP Opinion for ADCETRIS (brentuximab vedotin) as Consolidation Treatment in Post-Transplant Hodgkin Lymphoma3691
    May 17, 2016: Opdivo (nivolumab) Granted First Approval of a PD-1 Inhibitor in Hematology for the Treatment of Classical Hodgkin Lymphoma Patients Who Have Relapsed or Progressed After Auto-HSCT and Post-transplantation Brentuximab Vedotin by the FDA3702
    Apr 21, 2016: Affimed Presents Data on AFM13-mediated Innate/Adaptive Immune Crosstalk at the AACR Annual Meeting 20163721
    Apr 18, 2016: Seattle Genetics Highlights Data on ADCETRIS at the American Association for Cancer Research Annual Meeting3731
    Apr 18, 2016: Merck Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for KEYTRUDA (pembrolizumab) in Classical Hodgkin Lymphoma3731
    Apr 14, 2016: U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb s Supplemental Biologics License Application for Opdivo (nivolumab) for the Treatment of Classical Hodgkin Lymphoma Patients3741
    Mar 30, 2016: European Medicines Agency Validates Bristol-Myers Squibb s Application for Opdivo (nivolumab) for the Treatment of Classical Hodgkin Lymphoma Patients3741
Appendix3752
  Methodology3751
  Coverage3751
  Secondary Research3751
  Primary Research3751
  Expert Panel Validation3751
  Contact Us3751
  Disclaimer3761

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2016" Aug 10, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Hodgkin-Lymphoma-B-Cell-Hodgkin-Lymphoma-Pipeline-Review-H2-2016-2088-16357>
  
APA:
Global Markets Direct - Market Research. (2016). Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) - Pipeline Review, H2 2016 Aug 10, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Hodgkin-Lymphoma-B-Cell-Hodgkin-Lymphoma-Pipeline-Review-H2-2016-2088-16357>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.